Ovid Therapeutics Inc. filings document a Nasdaq-listed biopharmaceutical company focused on small-molecule medicines for CNS disorders involving neuronal hyperexcitability. Its regulatory record includes 8-K disclosures for clinical program updates, operating and financial results, leadership and compensation arrangements, Nasdaq compliance, and capital-structure events involving common stock, preferred stock, warrants and pre-funded warrants.
Proxy statements disclose board and executive governance, equity compensation, shareholder meeting proposals, authorized-share matters, and stockholder votes required under Nasdaq rules for securities issuances. The filings also record material agreements, risk and governance subjects, and exhibits related to the company’s OV350, OV4071 and OV329 development programs.
Insider Trading Alert: Barbara Gayle Duncan, Director at Ovid Therapeutics (OVID), received a stock option grant on February 20, 2025. The transaction details include:
- Granted 45,000 stock options to purchase common stock
- Exercise price set at $0.57 per share
- Options will vest fully on February 20, 2026, contingent on continuous service
- Options expire on February 19, 2035
This Form 4 filing, reported by the director's attorney-in-fact Jason Minio on June 18, 2025, represents a standard equity compensation grant for board service. The relatively low exercise price and one-year cliff vesting schedule suggest this is part of the company's regular director compensation program.
Ovid Therapeutics director Karen Bernstein received a stock option grant for 45,000 shares of common stock on February 20, 2025. The key details of this Form 4 filing include:
- Option exercise price set at $0.57 per share
- Options will vest fully on February 20, 2026, contingent on continuous service
- Expiration date is set for February 19, 2035
- The derivative securities are held directly by the reporting person
This grant represents a standard director compensation package and aligns the director's interests with shareholders through long-term equity incentives. The one-year cliff vesting schedule encourages retention while the ten-year exercise window provides flexibility in execution timing.